After the usual shenanigans on the market this morning, the implications of what it means to transition from a pre-commercial to a commercial company will begin to sink in and in my non-financial advice view, I speculate that sp will begin a solid trajectory of gains.
The announcement confirms that launch is happening this quarter and the current delay is at the hands of the FDA.
Even if only 20% of the potential suggested is captured, i.e $200m USD or approx $320m AUD a conservative 30x multiple of PE results in a Market Cap of $9.6B AUD or Share price of ~$7.57
V
Ann: Ryoncil Commercial Launch Update and Product Pipeline, page-30
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
-0.040(1.61%) |
Mkt cap ! $3.135B | |||
| Open | High | Low | Value | Volume |
| $2.47 | $2.47 | $2.34 | $9.610M | 3.975M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $2.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 30998 | 2 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |